Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 17/20 | 0.49 |
| ▸ | MAP2K2 | P36507 | 14/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.40 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6267078 | 0.89 | MAP2K1 (0.46) | MAP2K1MAP2K2MEN1KMT2ATDP1 | |
| SCHEMBL6855994 | 0.88 | MEN1 (0.53) | MAP2K1MAP2K2MEN1KMT2ATDP1 | |
| SCHEMBL27565258 | 0.86 | MEN1 (0.43) | MAP2K1MAP2K2MEN1KMT2ATDP1 | |
| SCHEMBL6858406 | 0.84 | MAP2K1 (0.65) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL6858379 | 0.84 | MEN1 (0.44) | MAP2K1MAP2K2MEN1KMT2ATDP1 | |
| SCHEMBL6851703 | 0.80 | IDO1 (0.41) | MAP2K1MEN1KMT2ATDP1TET2 | |
| SCHEMBL6265725 | 0.80 | MEN1 (0.57) | MAP2K1MAP2K2MEN1KMT2ATDP1 | |
| SCHEMBL4851710 | 0.79 | MAP2K1 (0.78) | MAP2K1MAP2K2MEN1KMT2ATDP1 | |
| SCHEMBL14594277 | 0.79 | MAP2K1 (0.62) | MAP2K1MAP2K2MEN1KMT2ATDP1 | |
| SCHEMBL29425477 | 0.79 | MAP2K1 (0.78) | MAP2K1MAP2K2MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1202724-B1 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER LAMBERT CO (US) | 2003-10-01 | — | — | EP | claimed |
| US-20030045521-A1 | Sulfohydroxamic acids and sulfohydroxamates and their use as MEK inhibitors | TECLE HAILE (US) | 2003-03-06 | — | — | US | claimed |
| JP-2003504401-A | — | — | 2003-02-04 | — | — | JP | claimed |
| US-6455582-B1 | TREATING CANCER | WARNER-LAMBERT COMPANY | 2002-09-24 | — | — | US | claimed |
| EP-1202724-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-05-08 | — | — | EP | claimed |
| EP-1144372-A1 | SULPHOHYDROXAMIC ACIDS AND SULPHOHYDROXAMATES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2001-10-17 | — | — | EP | claimed |
| WO-2001005393-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-01-25 | — | — | WO | claimed |
| WO-2000042002-A1 | SULPHOHYDROXAMIC ACIDS AND SULPHOHYDROXAMATES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | claimed |
| US-6835749-B2 | Sulfohydroxamic acid diarylamines; treating proliferative disease, cancer, stroke, heart failure, symptoms of xenograft rejection, osteoarthritis, rheumatoid arthritis, cystic fibrosis, hepatomegaly, Alzheimer's disease, etc. | WARNER LAMBERT COMPANY | 2004-12-28 | — | — | US | disclosed |
| EP-1202724-B1 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER LAMBERT CO (US) | 2003-10-01 | — | — | EP | disclosed |
| US-20030045521-A1 | Sulfohydroxamic acids and sulfohydroxamates and their use as MEK inhibitors | TECLE HAILE (US) | 2003-03-06 | — | — | US | disclosed |
| US-6455582-B1 | TREATING CANCER | WARNER-LAMBERT COMPANY | 2002-09-24 | — | — | US | disclosed |
| EP-1202724-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-05-08 | — | — | EP | disclosed |
| EP-1144372-A1 | SULPHOHYDROXAMIC ACIDS AND SULPHOHYDROXAMATES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001005393-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
| WO-2000042002-A1 | SULPHOHYDROXAMIC ACIDS AND SULPHOHYDROXAMATES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045521-A1 | Sulfohydroxamic acids and sulfohydroxamates and their use as MEK inhibitors | BRAF, MAP3K15, MAP3K1 | MAP2K1 44/4885MAP2K2 30/4885MEN1 3038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.